MOTS-c

Overview

MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a 16-amino acid peptide with a uniquely novel origin — it is encoded not by nuclear DNA like most peptides, but by a short open reading frame within the mitochondrial 12S rRNA gene. This makes MOTS-c one of a small class of mitochondrial-derived peptides (MDPs) — bioactive peptides produced by mitochondria that serve as signaling molecules between mitochondria, the nucleus, and other cellular compartments. First identified in 2015 by Lee et al. at the University of Southern California, MOTS-c represents a new category of endogenous metabolic regulator — one that is produced in response to exercise and metabolic stress and plays a central role in glucose metabolism, insulin sensitivity, and energy homeostasis. What makes MOTS-c particularly compelling is its classification as an exercise mimetic — endogenous MOTS-c levels increase approximately 11.9-fold in skeletal muscle following exercise and 1.6-fold in circulation during exercise. This means MOTS-c is a molecule the body naturally produces to mediate some of the metabolic benefits of physical activity. Plasma MOTS-c levels decline with age and are lower in people with obesity, insulin resistance, and type 2 diabetes — positioning it as a potential therapeutic target for metabolic disease and aging. It is not FDA approved and remains a research compound, but has been added to the WADA prohibited list reflecting its potential for performance enhancement.

Mechanism of Action

1. AMPK and SIRT1 Activation [1] — MOTS-c's primary mechanism involves activation of AMPK (AMP-activated protein kinase) — the master metabolic sensor — and SIRT1, both of which are central to exercise-induced metabolic adaptations. AMPK activation promotes glucose uptake via GLUT4 translocation, fatty acid oxidation, and mitochondrial biogenesis. SIRT1 activation supports epigenetic regulation of metabolic gene expression. Together these pathways reproduce key metabolic effects of exercise.
2. Nuclear Translocation During Stress [2] — Unlike most peptides that act at cell surface receptors, MOTS-c is uniquely transported to the nucleus during metabolic stress where it directly regulates nuclear gene expression — influencing genes related to metabolism, proteostasis, and stress response. This mitochondria-to-nucleus communication represents a novel signaling axis.
3. GLUT4 Upregulation [3] — MOTS-c increases GLUT4 glucose transporter expression and translocation to the cell surface in skeletal muscle, directly improving glucose uptake and insulin sensitivity — a mechanism shared with exercise and metformin.
4. Insulin Sensitivity Improvement [1] — MOTS-c improves insulin sensitivity in skeletal muscle by activating AMPK-dependent glucose uptake pathways, and has been shown to inhibit weight gain and insulin resistance caused by high-fat diet in animal models.
5. Anti-inflammatory Effects [2] — MOTS-c suppresses inflammatory markers including IL-1β and IL-6 in adipose tissue, reducing the chronic low-grade inflammation that drives metabolic dysfunction. This anti-inflammatory mechanism is particularly relevant in the context of obesity-associated metabolic disease.
6. Mitochondrial Biogenesis [3] — Through AMPK and SIRT1 activation, MOTS-c stimulates PGC-1α — the master regulator of mitochondrial biogenesis — promoting the creation of new, healthy mitochondria and improving overall mitochondrial function.

Key Research Areas

1. Insulin Resistance and Type 2 Diabetes [1] — The landmark 2015 study by Lee et al. in Cell Metabolism established MOTS-c as a regulator of metabolic homeostasis — demonstrating that MOTS-c administration reduces obesity and insulin resistance in high-fat diet mouse models. Blood MOTS-c levels are significantly lower in people with type 2 diabetes, gestational diabetes, and insulin resistance — establishing a clear clinical association.
2. Exercise Mimicry and Physical Performance [2] — A landmark 2021 Nature Communications study by Reynolds et al. demonstrated that MOTS-c treatment significantly enhanced physical performance in young, middle-aged, and old mice — and that late-life MOTS-c treatment increased healthspan. In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and circulation, confirming its role as an exercise-induced metabolic regulator.
3. Aging and Healthspan [2] — MOTS-c levels decline with age in parallel with declining metabolic function and physical capacity. The Reynolds et al. study showed intermittent MOTS-c treatment initiated late in life (equivalent to human old age) still produced meaningful improvements in physical capacity and healthspan in mice — suggesting therapeutic potential even when started later in life.
4. Cardiovascular Health [3] — Plasma MOTS-c levels are positively correlated with coronary endothelial function in humans, and MOTS-c improves endothelial function in animal models — suggesting cardiovascular protective effects beyond its metabolic benefits.
5. Menopause and Hormonal Metabolic Dysfunction [1] — MOTS-c treatment prevented weight gain and insulin resistance in an ovariectomized mouse model of menopause — suppressing inflammatory markers in adipose tissue and suggesting potential applications for metabolic dysfunction associated with hormonal changes.

Observed Benefits in Research

1. 11.9-fold increase in endogenous MOTS-c in skeletal muscle following exercise
2. Reduced obesity and insulin resistance in high-fat diet mouse models
3. Significantly enhanced physical performance across all age groups in mice
4. Late-life treatment improved healthspan in aged mice
5. Lower plasma levels consistently found in type 2 diabetes and insulin resistance
6. Improved endothelial function and cardiovascular markers
7. Prevention of menopause-associated metabolic dysfunction in animal models
8. Anti-inflammatory effects in adipose tissue

Pharmacokinetics

1. Structure: 16 amino acid peptide encoded by mitochondrial 12S rRNA gene
2. Origin: Mitochondrial-derived — unique among peptide therapeutics
3. Administration: Subcutaneous injection in research protocols
4. Endogenous regulation: Produced in response to exercise and metabolic stress
5. Age-related decline: Plasma levels decline with age and in metabolic disease

Research Limitations

(1) Most robust research is from animal models — human clinical trial data is limited. (2) No large-scale human RCTs have been completed. (3) Optimal dosing for human therapeutic use has not been established — animal doses vary widely (0.5–50 mg/kg). (4) Not FDA approved and added to the WADA prohibited list in 2024, reflecting both its performance-enhancing potential and unresolved regulatory status. (5) The mechanisms of action while well-studied in animals require further confirmation in humans. (6) Long-term safety data in humans is not available.

WADA Status

MOTS-c is listed on the WADA prohibited list and is banned in competitive sport. Athletes in WADA-governed competitions should not use MOTS-c.

Common Research Stacking

MOTS-c is studied alongside other metabolic peptides including AOD-9604 for fat metabolism and is positioned alongside Epitalon and NAD+ in longevity research given its role in mitochondrial function and aging.

References

1. PMC. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/
2. Nature Communications. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. 2021. https://www.nature.com/articles/s41467-020-20790-0
3. Frontiers in Physiology. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. 2025. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1602271/full